Paris, 25 November 2014, 5:45 Pm
Web conference
Masitinib in asthma - Safety and Efficacy Update
2 December 2014 (18h00 - 18h50 CET)
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of asthma with key opinion leaders from this disease.
The web conference call will be held on 2 December 2014 from 18h00 to 18h50 CET.
The web conference will provide the opportunity to understand:
- The current positioning of masitinib in severe asthma uncontrolled by oral corticosteroid, which represents the highest medical need
- The efficacy and safety update on the on-going phase 3 study
It will be followed by a Q&A session.
The following experts in this disease will animate the discussion and answer questions
- Pr. Pascal Chanez
Department of respiratory diseases
Timone University Hospital, Marseille, France
- Dr. Lavinia Davidescu
Department of pneumology
Clinical Hospital Oradea, Romania
- Pr. Gilles Devouassoux
Department of pneumology
Hospices Civiles de Lyon, France
- Dr. Jean-Pierre Kinet
Professor of Pathology at Harvard Medical School
Director of the Division of Allergy and Immunology at the Beth Israel Deaconess Medical Center
- Dr. Cesar Picado Valles
Hospital Clínic de Barcelona, Institut de Pneumologia
University of Barcelona, Spain
The presentation supporting this conference call will be made available on AB science web site upon completion of the web call.
About masitinib
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with sort term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in humans and animal health.
AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
Further information is available on AB Science's website: www.ab-science.com
This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.
* * *
AB Science - Financial Communication & Media Relations
contact@ab-science.com
